Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter for the development and commercialization of ESTELLE ® and DONESTA® in ChinaMithra to receive EUR 4.5 million in combined milestone payments at signature of the license agreements with additional combined regulatory milestones of EUR 1.2 millionMithra eligible to receive a combined total of EUR 8.5 million sales related milestones and additional high-single-digit to low-double-digit percent tiered royalties after launchESTELLE® to target an addressable contraceptive market in China valued at EUR 104 million annually (with a 5-year CAGR ~15%)1 DONESTA® to target an addressable menopause market in China valued at EUR 87 million annually (with a 5-year CAGR at ~10%)1 Liege, Belgium, 04 December 2023 – 07:00 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) with Gedeon Richter Plc.

Mithra和Gedeon Richter签署了在中国将ESTELLE®和DONESTA®商业化的条款负责人Mithra签署了与Gedeon Richter合作开发和商业化ESTELLE®和DONESTA®在ChinaMithra的二十年合作伙伴关系的条款负责人在签署许可协议时收到450万欧元的合并里程碑付款以及其他合并120万欧元的监管里程碑在launchESTELLE®之后，有资格获得总计850万欧元的销售相关里程碑和额外的高单位数到低单位数百分比分层特许权使用费，目标是中国可寻址的避孕市场，价值为每年1.04亿欧元（5年CAGR~15%）1Donesta®针对可寻址的更年期市场中国每年价值8700万欧元（5年CAGR约为10%）1比利时列日，2023年12月4日至07:00 CET-Mithra（Euronext Brussels:MITRA），一家致力于女性健康的公司，今天宣布与Gedeon Richter Plc签署具有约束力的条款（HoT）负责人。

related to an agreement for the development and commercialization of ESTELLE® and DONESTA® in China. ESTELLE® is the first estetrol-based combined oral contraceptive (15 mg estetrol (E4) / 3 mg drospirenone) and DONESTA® is Mithra’s investigational, next generation hormone therapy medicine containing estetrol (E4) for the treatment of the symptoms of menopause.

与ESTELLE®和DONESTA®在中国的开发和商业化协议有关。ESTELLE®是第一种基于estetrol的联合口服避孕药（15 mg estetrol（E4）/3 mg屈螺酮），DONESTA®是Mithra研究的含有estetrol（E4）的下一代激素治疗药物，用于治疗更年期症状。

Upon the finalization of the license agreements, Gedeon Richter will have the exclusive commercial rights for both ESTELLE® and DONESTA® in China. Gedeon Richter will perform and fund the clinical studies required to obtain marketing approvals in China. Upon the closing of the two licencing agreements, Mithra will receive a combined milestone payment of EUR .

在许可协议最终确定后，Gedeon Richter将在中国拥有ESTELLE®和DONESTA®的独家商业权利。Gedeon Richter将执行并资助获得中国市场批准所需的临床研究。在两项许可协议结束后，Mithra将收到欧元的综合里程碑付款。

Attachment

附件

2023-12-04_Mithra_Press-Release_Gedeon Richter China_FR

2023-12-04_Mithra_Press-Release_Gedeon Richter China_FR